For the Inventor, By the Inventor

Enter assignee name

Grand Cayman, Cayman Islands

Beigene, Ltd.

USPTO Granted Patents = 54

% Expired Patents = 7.4

CIPO Patents = 8

EPO Patents = 18

Trademarks = 5

Forward Citations = 664

Loading Chart...

Loading Chart...

44 inventors (with patents filed for the assignee):

Changyou Zhou (26 out of 45 patents)

Zhiwei Wang (18 out of 81 patents)

Guoliang Zhang (15 out of 23 patents)

4. Hexiang Wang (14 out of 18 patents)

5. Yunhang Guo (12 out of 25 patents)

6. Bo Ren (12 out of 13 patents)

7. Kang Li (11 out of 32 patents)

8. Tong Zhang (10 out of 88 patents)

9. Jing Li (7 out of 152 patents)

10. Jing Song (7 out of 15 patents)

11. Qi Liu (5 out of 103 patents)

12. Min Wei (4 out of 15 patents)

13. Haibo Zhao (4 out of 4 patents)

14. Hao Peng (4 out of 11 patents)

15. Geoffrey Kim (3 out of 3 patents)

Core Competencies:

BCL-2 Inhibitors

PD-1 Antibodies

PARP Inhibitors

Raf Kinase Inhibitors

Immunotherapy

Tyrosine Kinase Modulators

TLR7 Agonists

HPK1 Inhibitors

Anti-OX40 Antibodies

Combination Therapies

Cyclic Dinucleotides

Indoleamine Inhibitors

54 patents: Sort by Forward Citations

1. 12667560 - Co-administration of mirdametinib and lifirafenib for use in treating cancers (2026-06-30),

2. 12582604 - Stable solid dispersion of a B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor (2026-03-24),

3. 12435104 - Cyclic dinucleotides as sting agonists (2025-10-07),

4. 12286430 - Bcl-2 inhibitor (2025-04-29),

5. 12281119 - Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist (2025-04-21),

6. 12195449 - 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof (2025-01-14),

7. 12103974 - Anti-OX40 antibodies and methods of use (2024-10-01),

8. 12077536 - BCL-2 inhibitors (2024-09-03),

9. 11905294 - Imidazo[1,5-a]pyrazine derivatives as PI3Kδ inhibitors (2024-02-20),

10. 11875885 - Interoperable platform for reducing redundancy in medical database management (2024-01-16),

11. 11725012 - Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors (2023-08-15),

12. 11636930 - Interoperable platform for reducing redundancy in medical database management (2023-04-25),

13. 11597768 - Immunotherapy for hepatocellular carcinoma (2023-03-07),

14. 11555038 - Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof (2023-01-17),

15. 11512132 - Anti-PD-L1 antibodies and their use as therapeutics and diagnostics (2022-11-29),

Company Overview

Beigene, Ltd. is a biotechnology company based in Grand Cayman, specializing in the development of innovative cancer therapeutics. The company focuses on a range of core technologies, including BCL-2 inhibitors, PD-1 antibodies, and PARP inhibitors, aimed at advancing treatment options for various malignancies. With a commitment to immunotherapy and targeted therapies, Beigene is at the forefront of cancer research, striving to improve patient outcomes through novel therapeutic approaches.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

54 Patents

#19 in Grand Cayman

#23 in Cayman Islands

#13,140 in the World

Grand Cayman, Cayman Islands

Beigene, Ltd.

Forward Citations = 664

44 inventors:

Changyou Zhou (26 out of 45 patents)

Zhiwei Wang (18 out of 81 patents)

Guoliang Zhang (15 out of 23 patents)

4. Hexiang Wang (14 out of 18 patents)

5. Yunhang Guo (12 out of 25 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Beigene, Ltd.. Retrieved from https://idiyas.com/company/beigene

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…